Patents by Inventor Anne O'Kearney-McMullan

Anne O'Kearney-McMullan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
    Patent number: 8304417
    Abstract: The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such as a difumarate salt and a trihydrate and to pharmaceutical compositions containing such crystalline forms.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: November 6, 2012
    Assignee: AstraZeneca AB
    Inventors: James Gair Ford, James Francis McCabe, Anne O'Kearney-McMullan, Simon Mark Pointon, Lyn Powell, Philip O'Keefe, Mark Purdie, Jane Withnall
  • SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH
    Publication number: 20110207745
    Abstract: Solid forms comprising salts of 4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, compositions comprising the solid forms, methods of making the solid forms, and methods of their use for the treatment of various diseases and/or disorders are provided herein.
    Type: Application
    Filed: November 23, 2010
    Publication date: August 25, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Louis Diorazio, Andrew Hornby Dobson, Alison Norton, Anne O'Kearney-McMullan, Dedong Wu
  • Chemical Process
    Publication number: 20090099196
    Abstract: The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such as a difumarate salt and a trihydrate and to pharmaceutical compositions containing such crystalline forms.
    Type: Application
    Filed: December 14, 2005
    Publication date: April 16, 2009
    Inventors: James Gair Ford, James Francis McCabe, Anne O'Kearney-McMullan, Simon Mark Pointon, Lyn Powell, Philip O'Keefe, Mark Purdie, Jane Withnall
  • Novel Amination Process
    Publication number: 20070219372
    Abstract: Provided herein are novel processes for the preparation of intermediates that may be useful in the preparation of 5-Ht1b receptor antagonist useful in the treatment of depression, anxiety and other related diseases. The present processes may offer improved yields, purity, ease of preparation and isolation of intermediates and final product and more industrially useful reaction conditions and workability.
    Type: Application
    Filed: March 22, 2005
    Publication date: September 20, 2007
    Applicant: AstraZeneca AB
    Inventors: Mouloud Dekhane, Alison Norton, Anne O'Kearney-McMullan, Graham Robinson